

Active Ingredient Summary Table

Pain

Active Pharmaceutical Ingredient	Class	Activity
Amantadine Hydrochloride	Neuropathic agent; Analgesic	NMDA antagonist
Amitriptyline Hydrochloride	Neuropathic agent; Analgesic	Tricyclic antidepressant
Baclofen	Vitamin C; Antioxidant	GABA agonist; Central acting muscle relaxant
Capsaicin	Anesthetic	Binds to TRPV1 receptors
Carbamazepine	Corticosteroids; Anti-inflammatory	Sodium channel blocking
Clonidine Hydrochloride	Anesthetic	α_2 -receptor agonist; Norepinephrine blockade antihypertensive
Cyclobenzaprine Hydrochloride	Muscle relaxant	Central acting muscle relaxant; structurally related to tricyclic antidepressants
Dexamethasone Dexamethasone Sodium Phosphate	Anti-Inflammatory	Corticosteroid
Dextromethorphan Hydrobromide	Analgesic	NMDA antagonist
Diclofenac Sodium	NSAID; Analgesic	Selective COX-2 inhibitor
Dimethyl Sulfoxide (DMSO)	Anti-Inflammatory; Analgesic	Polar aprotic solvent
Doxepin Hydrochloride	Neuropathic agent; Analgesic	Tricyclic antidepressant
Flurbiprofen	NSAID; Analgesic	Nonselective COX inhibitor; Propionic acid derivative

Active Ingredient Summary Table

Pain

Gabapentin	Neuropathic agent; Analgesic	GABA analog; Voltage-sensitive calcium channel binding
Guaifenesin	Muscle relaxant	Muscle relaxant; Expectorant
Ibuprofen	NSAID; Analgesic	Nonselective COX inhibitor; Propionic acid derivative
Imipramine Hydrochloride	Neuropathic agent; Analgesic	Tricyclic antidepressant
Indomethacin	NSAID; Analgesic	Nonselective COX inhibitor; Indole acetic acid derivative
Ketamine Hydrochloride	Analgesic; Anesthetic	NMDA antagonist
Ketoprofen	NSAID; Analgesic	Nonselective COX inhibitor; Propionic acid derivative
Lidocaine Lidocaine Hydrochloride	Analgesic; Anesthetic	Fast acting, longer acting aminoethylamide
Loperamide Hydrochloride	Analgesic	μ -opioid receptor agonist
Magnesium Chloride	Muscle relaxant	Nutrient; Mineral; Muscle relaxant
Mefenamic Acid	NSAID; analgesic	Nonselective COX-1 and COX-2 inhibitor
Meloxicam	NSAID; analgesic	Selective inhibition of COX-1 over Cox-2
Methadone Hydrochloride	Narcotic; Analgesic	μ -opioid receptor agonist
Mexiletine Hydrochloride	Neuropathic agent; Analgesic	Anti-arrhythmic, Sodium channel blocking
Morphine Sulfate	Narcotic; Analgesic	μ -opioid receptor agonist

Active Ingredient Summary Table

Pain

Naproxen	NSAID; analgesic	Nonselective COX inhibitor; Propionic acid derivative
Nifedipine	Circulatory agent	Calcium-channel blocking; Improves blood flow; Antihypertensive
Orphenadrine Citrate	Central acting muscle relaxant	Tertiary amine antimuscarinic; NMDA antagonist
Pentoxifylline	Circulatory agent	Methylated xanthine derivative; Nonselective phosphodiesterase inhibitor
Phenytoin	Neuropathic agent; Analgesic	Sodium channel blocking
Piroxicam	NSAID; Analgesic	Nonselective COX inhibitor; Oxicam derivative enolic acid
Prilocaine Prilocaine Hydrochloride	Analgesic; Anesthetic	Intermediate acting amino amide
Tetracaine Tetracaine Hydrochloride	Analgesic; Anesthetic	Long acting amino ester
Topiramate	Neuropathic agent; Analgesic	Sodium channel blocking; Anti-convulsive
Tramadol Hydrochloride	Analgesic	SNRI, Weak μ -opioid receptor agonist
Verapamil Hydrochloride	Circulatory agent; Smooth muscle relaxant	Calcium channel blocking; anti-arrhythmic agent

References:

1. Altman, R. D., & Barthel, H. R. (2011). Topical therapies for osteoarthritis. *Drugs*, 71(10), 1259-1279. doi:10.2165/11592550-000000000-00000.
2. Argoff, C. E. (2013). Topical analgesics in the management of acute and chronic pain. *Mayo Clinic Proceedings*, 88(2), 195-205. doi:10.1016/j.mayocp.2012.11.015.

Pain

3. Boardman, L. A., Cooper, A. S., Blais, L. R., & Raker, C. A. (2008). Topical gabapentin in the treatment of localized and generalized vulvodynia. *Obstetrics and Gynecology*, 112(3), 579-585. doi:10.1097/AOG.0b013e3181827c77.
4. Bock, U., Krause, W., Otto, J., & Haltner, E. (2004). [Comparative in vitro and in vivo studies on the permeation and penetration of ketoprofen and ibuprofen in human skin]. *Vergleichende In-vitro- Und In-vivo- Studien Zur Permeation Und Penetration Von Ketoprofen Und Ibuprofen An Humaner Haut.*, 54(9), 522-529. doi:10.1055/s-0031-1297007.
5. Campbell, C. M., Kipnes, M. S., Stouch, B. C., Brady, K. L., Kelly, M., Schmidt, W. K., . . . Campbell, J. N. (2012). Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. *Pain*, 153(9), 1815-23. doi:10.1016/j.pain.2012.04.014
6. Cagnie, B., Vinck, E., & Rimbaut, S. (2003). Phonophoresis versus topical application of ketoprofen: Comparison between tissue and plasma levels. *Physical Therapy*. 2003 Aug;83(8):707-12.
7. Cannavino, C. R., Abrams, J., Palinkas, L. A., Saglimbeni, A., & Bracker, M. D. (2003). Efficacy of transdermal ketoprofen for delayed onset muscle soreness. *Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine*, 13(4), 200-208.
8. Chi, S., Tan, H., & Chun, H. (1999). Antiinflammatory and analgesic transdermal gel containing ketoprofen. EP Patent 0,672,422.
9. Cordero, J. A., Alarcon, L., & Escribano, E. (1997). A comparative study of the transdermal penetration of a series of nonsteroidal antiinflammatory drugs. *Journal of Pharmaceutical Science*. 1997 Apr;86(4):503-8.
10. Gammaitoni, A., Gallagher, R. M., & Welz-Bosna, M. (2000). Topical ketamine gel: Possible role in treating neuropathic pain. *Pain Medicine (Malden, Mass.)*, 1(1), 97-100. doi:10.1046/j.1526-4637.2000.00006.x.
11. Goi, N., Morishita, K., Taniguchi, A., Ishii, T., & Saitoh, K. (2010). Evaluation of percutaneous permeation of flurbiprofen and ketoprofen after application of transdermal patches using a lateral sectioning approach in hairless rats. *Pharmaceutical Development and Technology*, 15(6), 658-665.
12. Heyneman, C. A., Lawless-Liday, C., & Wall, G. C. (2000). Oral versus topical nsais in rheumatic diseases: A comparison. *Drugs*. 2000 Sep;60(3):555-74.
13. Komatsu, T., & Sakurada, T. (2012). Comparison of the efficacy and skin permeability of topical NSAID preparations used in europe. *European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences*, 47(5), 890-5. doi:10.1016/j.ejps.2012.08.016.
14. Kopsky, D. J., & Hesselink, J. M. K. (2012). High doses of topical amitriptyline in neuropathic pain: Two cases and literature review. *Pain Pract*, 12(2), 148-153. doi:10.1111/j.1533- 2500.2011.00477.x.
15. Lynch, M. E., Clark, A. J., & Sawynok, J. (n.d.). A pilot study examining topical amitriptyline, ketamine, and a combination of both in the treatment of neuropathic pain. *The Clinical Journal of Pain*, 19(5), 323-8.
16. Lynch, M. E., Clark, A. J., Sawynok, J., & Sullivan, M. J. (2005). Topical amitriptyline and ketamine in neuropathic pain syndromes: An open-label study. *The Journal of Pain : Official Journal of the American Pain Society*, 6(10), 644-9. doi:10.1016/j.jpain.2005.04.008.
17. Massey, T., Derry, S., Moore, R. A., & McQuay, H. J. (2010). Topical nsais for acute pain in adults. *The Cochrane Database of Systematic Reviews*, (6), CD007402. doi:10.1002/14651858.CD007402.pub2.
18. Mazières, B. (2005). Topical ketoprofen patch. *Drugs R D*, 6(6), 337-344.
19. McCarberg, B., & D'Arcy, Y. (2013). Options in topical therapies in the management of patients with acute pain. *Postgraduate Medicine*, 125(4 Suppl 1), 19-24.
20. Morel, V., le Pickering, G., Etienne, M., Dupuis, A., Privat, A. M., Chalus, M., . . . Daulhac, L. (2014). Low doses of dextromethorphan have a beneficial effect in the treatment of neuropathic pain. *Fundamental & Clinical Pharmacology*. doi:10.1111/fcp.12076
21. Nowak, Ł., Zurowski, D., Dobrogowski, J., Wordliczek, J., & Thor, P. J. (2012). Pentoxifylline modifies central and peripheral vagal mechanism in acute and chronic pain models. *Folia Medica Cracoviensia*, 52(1-2), 83-95. Nyirjesy, P., Lev-Sagie, A., Mathew,

Pain

22. L., & Culhane, J. F. (2009). Topical amitriptyline-baclofen cream for the treatment of provoked vestibulodynia. *Journal of Lower Genital Tract Disease*, 13(4), 230. doi:10.1097/LGT.0b013e31819663ee.
23. Pagano, R., & Wong, S. (2012). Use of amitriptyline cream in the management of entry dyspareunia due to provoked vestibulodynia. *Journal of Lower Genital Tract Disease*, 16(4), 394-397.
24. Pomerleau, A. C., Gooden, C. E., Fantz, C. R., & Morgan, B. W. (2014). Dermal exposure to a compounded pain cream resulting in severely elevated clonidine concentration. *Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology*, 10(1), 61-4. doi:10.1007/s13181-013-0331-x
25. Rhee, G. J., Woo, J. S., & Hwang, S. J. (1999). Topical oleo-hydrogel preparation of ketoprofen with enhanced skin permeability. *Drug Dev Ind Pharm*. 1999 Jun;25(6):717-26.
26. Richards, H., Thomas, C. P., Bowen, J. L., & Heard, C. M. (2006). In-vitro transcutaneous delivery of ketoprofen and polyunsaturated fatty acids from a pluronic lecithin organogel vehicle containing fish oil. *The Journal of Pharmacy and Pharmacology*, 58(7), 903-908. doi:10.1211/jpp.58.7.0004.
27. Stanos, S. P., & Galluzzi, K. E. (2013). Topical therapies in the management of chronic pain. *Postgraduate Medicine*, 125(4 Suppl 1), 25-33.
28. White, R. L. (2006). Ketoprofen gel as an adjunct to physical therapist management of a child with sever disease. *Physical Therapy*, 86(3), 424-433.
29. Uzaraga, I., Gerbis, B., Holwerda, E., Gillis, D., & Wai, E. (2012). Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: A pilot study. *Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer*, 20(7), 1515-1524. doi:10.1007/s00520-011-1240-7.
30. Vakili, A., Shirvanian, M., Safakhah, H., & Rashidy-Pour, A. (2011). Pentoxifylline decreases allodynia and hyperalgesia in a rat model of neuropathic pain. *Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences*, 19(4), 306-11.
31. Zeigler, D., Lynch, S. A., Muir, J., Benjamin, J., & Max, M. B. (1992). Transdermal clonidine versus placebo in painful diabetic neuropathy. *Pain*, 48(3), 403-8.